EUVIMEDEUVIMED entdecken
Crossref

Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans

Randi E Brown, Jennifer I Lissemore, Kenneth F Shinozuka, John P Coetzee, Afik Faerman, Clayton A Olash, Andrew D Geoly, Derrick M Buchanan, Kirsten N Cherian, Anna Chaiken, Ahmed Shamma, Malvika Sridhar und 5 weitere

Journal of Affective Disorders · 2026-02 · 395 · 120722

DOI: 10.1016/j.jad.2025.120722 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026-02. Verfasst von Randi E Brown und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, United States; VA Palo Alto Health Care Syst…. Hauptthemen laut MEDLINE: Stress Disorders, Post-Traumatic, Veterans, Ibogaine, Magnesium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: Saisei Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ibogaine is an atypical psychedelic that evokes unique subjective effects, including mystical experiences. Mystical experiences have shown a mediating effect on clinical improvements following treatment with several psychedelic substances; however, the relationship between mystical experiences and clinical outcomes following ibogaine remains unclear. We examined the association between mystical experiences during ibogaine and subsequent changes in PTSD severity. We also explored the relationship between mystical experiences and several electroencephalography (EEG) measures found to underlie some of ibogaine's therapeutic effects. Our study included 30 male Veterans with traumatic brain injury from repeated blast/combat exposures who underwent magnesium-ibogaine therapy. We assessed mystical experiences post-treatment using the Mystical Experiences Questionnaire (MEQ30). PTSD severity and resting-state EEG assessments occurred at baseline and immediately and 1-month post-treatment. In linear mixed models, we used the time by MEQ30 interaction to assess the relationship between MEQ30 and changes in PTSD severity and EEG measures after treatment. Participants reporting greater intensity of mystical experiences following magnesium-ibogaine exhibited larger reductions in PTSD both immediately and one month after treatment (time by MEQ30 interaction for change from baseline: immediate post-treatment Badj = -5.89, padj < 0.001; 1-month post-treatment Badj = -4.45, padj = 0.007). Greater intensity of mystical experiences was also associated with larger reductions in peak alpha frequency one month after treatment (Badj = -0.38, padj = 0.006). These findings suggest that mystical experiences may contribute to improvements in PTSD following magnesium-ibogaine. Greater mystical experiences during ibogaine treatment may also be related to persisting decreases in peak alpha frequency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stress Disorders, Post-TraumaticVeteransIbogaineMagnesiumHallucinogensMysticismHumansMaleAdultElectroencephalographyMiddle AgedTreatment OutcomeSurveys and QuestionnairesSeverity of Illness Index

Stichwörter der Autor:innen

IbogaineIbogaine-magnesiumMISTICMystical experiencePTSDPeak alpha frequency

Substanzen

IbogaineMagnesiumHallucinogens

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, United States; VA Palo Alto Health Care System, Women's Operational Military Exposure Network Center of Excellence…
  • Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, United States.
  • Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Charleston, SC, United States.
  • VA Palo Alto Health Care System, Women's Operational Military Exposure Network Center of Excellence (WOMEN CoE), Palo Alto, CA, United States; Department of Neurosurgery, Stanford University School of Medicine, Palo Alt…

Förderung

  • Saisei Foundation

Zitieren

APA

Brown, R. E., Lissemore, J. I., Shinozuka, K. F., Coetzee, J. P., Faerman, A., Olash, C. A., Geoly, A. D., Buchanan, D. M., Cherian, K. N., Chaiken, A., Shamma, A., Sridhar, M., Hunegnaw, S. A., Johnson, N. D., Rolle, C. E., Adamson, M. M., & Williams, N. R. (2026). Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans. Journal of Affective Disorders, 395, 120722. https://doi.org/10.1016/j.jad.2025.120722

Vancouver

Brown RE, Lissemore JI, Shinozuka KF, Coetzee JP, Faerman A, Olash CA, et al. Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans. Journal of Affective Disorders. 2026;395:120722. doi:10.1016/j.jad.2025.120722

BibTeX
@article{Brown2026,
  author = {Brown, Randi E and Lissemore, Jennifer I and Shinozuka, Kenneth F and Coetzee, John P and Faerman, Afik and Olash, Clayton A and Geoly, Andrew D and Buchanan, Derrick M and Cherian, Kirsten N and Chaiken, Anna and Shamma, Ahmed and Sridhar, Malvika and Hunegnaw, Saron A and Johnson, Noriah D and Rolle, Camarin E and Adamson, Maheen M and Williams, Nolan R},
  title = {Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans},
  journal = {Journal of Affective Disorders},
  year = {2026},
  volume = {395},
  pages = {120722},
  doi = {10.1016/j.jad.2025.120722}
}
Kostenlos starten →